This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignees: Agilent Technologies, Inc., Merck Sharp + Dohme Corp., Merck Sharp & Dohme LLC. Active years: 2020-2026.
Company Filing History:
3 out of 4,730 
2 out of 2,405 
1 out of 67 Years Active: 2020-2026
Title: Greg Angelides: Innovator in Anti-PD Therapy
Introduction
Greg Angelides is a notable inventor based in Philadelphia, PA (US). He has made significant contributions to the field of medical therapies, particularly in the area of anti-PD treatments. With a total of 3 patents, his work focuses on improving the eligibility criteria for patients undergoing such therapies.
Latest Patents
Angelides' latest patents include innovative methods for determining the eligibility of subjects with malignancies for treatment with anti-PD therapeutic agents. His patents detail a Combined Positive Score (CPS) approach for evaluating tumor tissue samples. These methods aim to enhance the precision of treatment eligibility, thereby improving patient outcomes.
Career Highlights
Throughout his career, Greg Angelides has worked with prominent companies in the pharmaceutical and biotechnology sectors. Notable employers include Agilent Technologies, Inc. and Merck Sharp & Dohme Corp. His experience in these organizations has allowed him to develop and refine his innovative ideas in the medical field.
Collaborations
Angelides has collaborated with talented professionals such as Karina Kulangara and Nancy Zhang. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Greg Angelides stands out as an influential inventor in the realm of anti-PD therapy. His innovative approaches and collaborations have the potential to significantly impact patient care in oncology.